August has seen a slew of executive hires, exits and layoffs across the healthcare sector. For example, OpenAI, Veradigm and Qure.ai welcomed new executives. There were also layoffs at organizations including BioNTech, CentraCare and Emory Healthcare. The post Healthcare Moves: A Monthly Summary of Hires, Exits and Layoffs appeared first on MedCity News.
Rebecca Kasen has seen and heard things in recent years in and around Michigan’s capital city that she never would have expected. “It’s a very weird time in our lives,” said Kasen, executive director of the Women’s Center of Greater Lansing. Last November, a group of people were captured on surveillance video early one morning…
Venteur’s $20 million funding round was led by Informed Ventures and American Family Ventures. In total, the company has raised $30 million. The post Venteur Raises $20M To Help Employers Administer ICHRAs appeared first on MedCity News.
In the past few years, state and local governments across the U.S. have begun spending billions in opioid settlements paid by companies accused of fueling the overdose crisis. But where is that money going, who is getting it, and is it doing any good? KFF Health News, partnering with the Johns Hopkins Bloomberg School of…
“I’d like to see Generalized Cost Effectiveness Analysis become the norm for how we assess value.” – Rep. Jake Auchincloss (D-MA 4th District) See the full interview here. To learn more about GCEA, check out the GCEA User Guide published last year.
Coultreon Biopharma’s lead drug candidate, acquired from Galapagos, is a small molecule designed to selectively inhibit a novel immunology target called SIK3. The Series A financing will support Phase 2 clinical trials in psoriasis and ulcerative colitis. The post Immunology-Focused Coultreon Adds $125M for Pills That Pack the Punch of Injectable Biologics appeared first on…
Braveheart Bio is preparing to advance to Phase 3 testing in obstructive hypertrophic cardiomyopathy, or oHCM. The startup says its small molecule could have safety advantages over Camzyos, a Bristol Myers Squibb capsule projected to become a blockbuster seller in this indication. The post Braveheart Bio Bags $185M for Drug That Could Rival a Bristol…
Sarah Emond on Prescription for Better Access. “Nothing will have more impact on workers’ comp than significant cuts to Medicaid.”“So one can only assume that we’re not picking flu strains this year.”SLR: Palliative care effectiveness/cost effectivenessNBER: Economics of Artificial Intelligence
More Americans than expected enrolled in Affordable Care Act health insurance plans for this year, after premium subsidies were dramatically cut — but it remains to be seen whether they’ll keep the coverage as their costs mount. It’s all part of a drama that roiled the ACA’s 2026 open enrollment period. Congressional debate over whether…
Value-based care promises to right the wrongs of fee-based healthcare. But today, we’re a long way from a value-based system. One way to get there faster? Prioritize access to data. The post Redesigning Healthcare: How Accessible Data Leads to Better Care appeared first on MedCity News.